Retrospective observational study of the conditions of use, safety and efficacy of MYLOTARG® (Gemtuzumab Ozogamicin, GO) in the treatment of patients with newly diagnosed CD33-positive acute myeloid leukaemia (AML). (MYLobs)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Yes
• Check completeness:
  Yes
• Check stability:
  Yes
• Check logical consistency:
  Yes

Data characterisation

• Data characterisation conducted:
  Yes